NPH insulin

NPH insulin
Nazivi
	Drugi nazivi Humulin N, Humulin N Pen, Humulin® N, Novolin N
Identifikacija
CAS broj	53027-39-7 ;
DrugBank	DB08914;
Farmakologija
Načini upotrebe	Subkutano
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	verifikuj (šta je ?)
	Reference infokutije

NPH insulin (neutralni protaminski Hagedorn, izofanski insulin) brzodelujući je insulin koji se koristi za poboljšanje glicemijske kontrole. On se proizvodi pomoću genetički modifikovane bakterije Escherichia coli. Ljudska suspenzija insulina izofana se sastoji od kristaline suspenzije ljudskog insulina sa protaminom i cinkim. Tak kombinaci daje intermedijarno delujući insulin sa sporijim početkom dejstva i dužim trajanjem od normalnog ljudskog insulina.^[1]^[2]^[3]^[4]^[5]^[6]

Reference[uredi | uredi izvor]

^ Lepore, M.; Pampanelli, S.; Fanelli, C.; Porcellati, F.; Bartocci, L.; Di Vincenzo, A.; Cordoni, C.; Costa, E.; Brunetti, P.; Bolli, G. B. (decembar 2000). „Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro”. Diabetes. 49 (12): 2142—8. PMID 11118018. doi:10.2337/diabetes.49.12.2142. CS1 održavanje: Format datuma (veza)
^ Owens, D. R.; Coates, P. A.; Luzio, S. D.; Tinbergen, J. P.; Kurzhals, R. (jun 2000). „Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: Comparison with NPH insulin and the influence of different subcutaneous injection sites”. Diabetes Care. 23 (6): 813—9. PMID 10841002. doi:10.2337/diacare.23.6.813. CS1 održavanje: Format datuma (veza)
^ Danne, T.; Lüpke, K.; Walte, K.; von Schuetz, W.; Gall, M. A. (novembar 2003). „Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes”. Diabetes Care. 26 (11): 3087—92. PMID 14578244. doi:10.2337/diacare.26.11.3087. CS1 održavanje: Format datuma (veza)
^ Owens, D. R.; Bolli, G. B. (2008). „Beyond the era of NPH insulin--long-acting insulin analogs: Chemistry, comparative pharmacology, and clinical application”. Diabetes Technology & Therapeutics. 10 (5): 333—349. PMID 18715209. doi:10.1089/dia.2008.0023.
^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Nucleic Acids Res (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. |first2= zahteva |last2= u Authors list (pomoć); |first3= zahteva |last3= u Authors list (pomoć); |first4= zahteva |last4= u Authors list (pomoć); |first5= zahteva |last5= u Authors list (pomoć); |first6= zahteva |last6= u Authors list (pomoć); |first7= zahteva |last7= u Authors list (pomoć); |first8= zahteva |last8= u Authors list (pomoć)

Literatura[uredi | uredi izvor]

Baganz, H. M.; Carfagno, S. C.; Cowan, B. Y.; Dillon, E. S. (1951). „NPH insulin; its comparison with previous insulin regimens”. The American Journal of the Medical Sciences. 222 (1): 1—6. PMID 14846799. S2CID 33147032. doi:10.1097/00000441-195107000-00001.
Burnham, D. K. (1951). „Insulin and insulin mixtures; nph insulin”. California Medicine. 75 (6): 412—415. PMC 1521099 . PMID 14886746.
Lacey, A. H. (1952). „A comparison of preparations of NPH insulin”. The Journal of Pharmacology and Experimental Therapeutics. 105 (2): 196—202. PMID 14928221.
Deckert, T.; Hansen, B.; Kølendorf, K.; Poulsen, J. S.; Smith, M. (1982). „Absorption of NPH-insulin from subcutaneous tissue: A methodological study in pigs”. Acta Pharmacologica et Toxicologica. 51 (1): 30—37. PMID 6751023. doi:10.1111/j.1600-0773.1982.tb01059.x.
Kølendorf, K.; Bojsen, J. (1982). „Kinetics of subcutaneous NPH insulin in diabetics”. Clinical Pharmacology and Therapeutics. 31 (4): 494—500. PMID 7060331. S2CID 25486753. doi:10.1038/clpt.1982.66.

Spoljašnje veze[uredi | uredi izvor]

NPH insulin

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Lepore, M.; Pampanelli, S.; Fanelli, C.; Porcellati, F.; Bartocci, L.; Di Vincenzo, A.; Cordoni, C.; Costa, E.; Brunetti, P.; Bolli, G. B. (decembar 2000). „Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro”. Diabetes. 49 (12): 2142—8. PMID 11118018. doi:10.2337/diabetes.49.12.2142. CS1 održavanje: Format datuma (veza)

[2] Owens, D. R.; Coates, P. A.; Luzio, S. D.; Tinbergen, J. P.; Kurzhals, R. (jun 2000). „Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: Comparison with NPH insulin and the influence of different subcutaneous injection sites”. Diabetes Care. 23 (6): 813—9. PMID 10841002. doi:10.2337/diacare.23.6.813. CS1 održavanje: Format datuma (veza)

[3] Danne, T.; Lüpke, K.; Walte, K.; von Schuetz, W.; Gall, M. A. (novembar 2003). „Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes”. Diabetes Care. 26 (11): 3087—92. PMID 14578244. doi:10.2337/diacare.26.11.3087. CS1 održavanje: Format datuma (veza)

[4] Owens, D. R.; Bolli, G. B. (2008). „Beyond the era of NPH insulin--long-acting insulin analogs: Chemistry, comparative pharmacology, and clinical application”. Diabetes Technology & Therapeutics. 10 (5): 333—349. PMID 18715209. doi:10.1089/dia.2008.0023.

[5] Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[6] Nucleic Acids Res (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. |first2= zahteva |last2= u Authors list (pomoć); |first3= zahteva |last3= u Authors list (pomoć); |first4= zahteva |last4= u Authors list (pomoć); |first5= zahteva |last5= u Authors list (pomoć); |first6= zahteva |last6= u Authors list (pomoć); |first7= zahteva |last7= u Authors list (pomoć); |first8= zahteva |last8= u Authors list (pomoć)

[1]

[2]

[3]

[4]

[5]

[6]